Non Hodgkin Lymphoma Clinical Trial

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma


The purpose of this study is to confirm that the pharmacokinetics of ibrutinib in pediatric participants is consistent with that in adults (part 1) and to assess efficacy (event-free survival [EFS]) of ibrutinib in combination with rituximab, ifosfamide, carboplatin, and etoposide (RICE) or rituximab, vincristine, ifosfamide, carboplatin, and idarubicin (RVICI) background therapy compared to RICE or RVICI background therapy alone (part 2).

View Full Description

Full Description

This is a Phase 3, randomized (study medication assigned to participants by chance), open-label (identity of study drug will be known to participant and study staff), controlled study which consists of two parts: Part 1 and Part 2. The Part 1 is a pharmacokinetic run-in part, which will be conducted before starting the randomized part (Part 2) of the study and Part 2 is a randomized and open-label study. Part 1 and Part 2 of the study will be conducted in 3 phases: a Pretreatment (Screening) Phase (Up to 14 days before administration of study drug), a Treatment Phase, and a Posttreatment Phase. The Treatment Phase will extend from enrollment (in Part 1) or randomization (in Part 2) until 1 of the following: 1) completion of 3 cycles of therapy, 2) transplantation, if clinically indicated, or 3) progressive disease (PD), whichever comes first. The Posttreatment Phase will continue until death, loss to follow up, consent withdrawal, or study end, whichever occurs first. The end of study is defined as when approximately 60 event-free survival (EFS) events have occurred in Part 2 (death, disease progression, or lack of complete response [CR] or partial response [PR] after 3 cycles of treatment based on blinded independent event review), or the sponsor terminates the study, whichever comes first. Participants in Part 1 will be 1 to less than (<) 18 years old. Participants in Part 2 will be 1 to 30 years old. Participants will be primarily evaluated for pharmacokinetics in part 1 and efficacy (EFS) of ibrutinib in combination with RICE or RVICI background therapy compared to RICE or RVICI background therapy alone in part 2. Participants' safety will be monitored throughout the study.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participants with 1 to less than (<) 18 years of age (Part 1 only), or 1 to 30 years of age, inclusive, if initial diagnosis of mature B-cell non-Hodgkin lymphoma (NHL) occurred at <18 years of age (Part 2 only)
Participants must be in first recurrence and have received only one prior line of therapy or have disease that is primarily refractory to conventional therapy
Participants must have at least 1 of the following: 1 site of measurable disease greater than (>) 1 centimeter (cm) in the longest diameter and >1 cm in the shortest diameter by radiological imaging; bone marrow involvement; cerebrospinal fluid with blasts present
Participants with lansky-Karnofsky score of greater than or equal to (>=) 50
Adolescent women/young women of childbearing potential must have a negative highly sensitive serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at Screening before enrollment/randomization. Adolescent/young women who are pregnant or breastfeeding are ineligible for this study

Exclusion Criteria:

Participants with ongoing anticoagulation treatment with warfarin or equivalent vitamin K antagonists (example phenprocoumon), or ongoing treatment with agents known to be strong CYP3A4/5 inhibitors, or has taken any disallowed therapies as noted in Section 8.2, Prohibited Medications, before the planned first dose of study drug
Participants with inherited or acquired bleeding disorders
Participants with clinically significant arrhythmias, complex congenital heart disease, or left ventricular ejection fraction (LVEF) <50 percent (%) or shortening fraction (SF) <=28%
Participants with known history of human immunodeficiency virus (HIV) or active Hepatitis B or C virus
Participants with any condition that could interfere with the absorption or metabolism of ibrutinib including malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
Participants with known allergies, hypersensitivity, or intolerance to ibrutinib or its excipients (refer to Investigator's Brochure)
A diagnosis of post-transplant lymphoproliferative disease (PTLD)
Participants who are within 6 months of an allogeneic bone marrow transplant
Participants who have had prior exposure to ibrutinib

Study is for people with:

Non Hodgkin Lymphoma


Phase 3

Estimated Enrollment:


Study ID:


Recruitment Status:



Janssen Research & Development, LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?


There is 1 Location for this study

See Locations Near You

Los Angeles California, , United States

Orange California, , United States

Palo Alto California, , United States

Aurora Colorado, , United States

Washington District of Columbia, , United States

Atlanta Georgia, , United States

Baltimore Maryland, , United States

Boston Massachusetts, , United States

New York New York, , United States

Valhalla New York, , United States

Charlotte North Carolina, , United States

Cincinnati Ohio, , United States

Columbus Ohio, , United States

Philadelphia Pennsylvania, , United States

Dallas Texas, , United States

Salt Lake City Utah, , United States

Milwaukee Wisconsin, , United States

Brussel , , Belgium

Leuven , , Belgium

Barretos , , Brazil

Curitiba , , Brazil

Sao Paulo , , Brazil

São Paulo , , Brazil

Plovdiv , , Bulgaria

Sofia , , Bulgaria

Halifax Nova Scotia, , Canada

Toronto Ontario, , Canada

Brno , , Czechia

Praha , , Czechia

Bordeaux , , France

Lille , , France

Lyon , , France

Marseille , , France

Nantes , , France

Toulouse , , France

Vandoeuvre les Nancy , , France

Villejuif , , France

Berlin , , Germany

Freiburg , , Germany

Kiel , , Germany

München , , Germany

Münster , , Germany

Budapest , , Hungary

Debrecen , , Hungary

Seoul , , Korea, Republic of

Rotterdam , , Netherlands

Utrecht , , Netherlands

Krakow , , Poland

Warszawa , , Poland

Wroclaw , , Poland

Bucuresti , , Romania

Cluj-Napoca , , Romania

Oradea , , Romania

Timisoara , , Romania

Ekaterinburg , , Russian Federation

Moscow , , Russian Federation

St. Petersburg , , Russian Federation

Barcelona , , Spain

Esplugues de Llobregat , , Spain

Madrid , , Spain

Valencia , , Spain

Gothenburg , , Sweden

Kaohsiung , , Taiwan

Taipei , , Taiwan

Taoyuan , , Taiwan

Ankara , , Turkey

Izmir , , Turkey

Kiev , , Ukraine

Birmingham , , United Kingdom

Cambridge , , United Kingdom

Leeds , , United Kingdom

Liverpool , , United Kingdom

London , , United Kingdom

Manchester , , United Kingdom

Newcastle , , United Kingdom

Sheffield , , United Kingdom

Surrey , , United Kingdom

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma


Phase 3

Estimated Enrollment:


Study ID:


Recruitment Status:



Janssen Research & Development, LLC

How clear is this clinincal trial information?


Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.